Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237 (Kidney International (2021) 100(1) (225–237), (S0085253820314186), (10.1016/j.kint.2020.10.046))

DOI of original article: https://doi.org/10.1016/j.kint.2020.10.046 The authors regret that the minimum age at time of first infusion value was reported incorrectly. The original reported age at time of first infusion, median (range), years, was 5.2 (0.5–17.3). The correct age at time of first infusion, median (range), years, is 5.2 (0.9–17.3). These errors have been corrected in the original article online. The authors would like to apologize for any inconvenience caused.